AR and breast cancer: Since ERα needs a co-regulatory protein SRC-3 to recruit p300 while AR can bind to p300 directly, AR may obtain an advantage in the competition with ERα, resulting in suppression of ER signaling; the activation of AR, therefore, demonstrated an inhibitive effect on ER + ve breast cancer cells [52].